CKD-397 Drug-drug Interaction Study (B)

Inclusion Criteria: * Healthy man age 19 years or more and less than 55 years old at the time of screening. * BMI more than 17.5kg / m2 and less than 30.5kg / m2 and weight more than 55kg * Subject without congenital or chronic diseases and no psychotic symptoms or findings from the medical examination. * Suitable subject who is determined by laboratory tests such as hematology tests, blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as ECG test. * Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital IRB. * Subjects who are able to comply with all scheduled visits, laboratory tests and other procedures. Exclusion Criteria: * Subject who has a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is clinically significant (Except untreated asymptomatic seasonal allergies at the time of administration) * Subject who has a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption. * Showing the value that corresponds to following laboratory parameters: AST or AST \> 2\* upper limit of normal range. * Alcohol \> 210g/week, within 6 months prior to the screening. * Taking the medication involved in other clinical trials within two months before the first dose medication characters. * Sitting Systolic Blood Pressure ≥ 140 mmHg, Diastolic Blood Pressure ≥ 90 mmHg at the time of screening. * History of alcohol or drug abuse, within 1 year * Positive result in urine drug test(Amphetamines, Cocaine, Opioid, Benzodiazepines, Cannabinoid) * Positive result in Serology test(Hepatitis B, Hepatitis C, HIV(Human Immunodeficiency Virus), TPPA(qual)). * Subject who takes an abnormal meal which can affect the ADME of drug. * Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals within 30days prior to the first dosing. * Smoker (\> 20cigarettes/day) * Subjects who takes ETC or OTC medicine within 10days before the first IP administration. * Subject who done the whole blood donation within two months or component blood donation within 1 month prior to the first dosing. * Subject who can increase risk due to clinical test and administration of drugs or has Severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results. * Subject with taking any forms of organic nitrate periodically and/or intermittently. * Subject with known hereditary degenerative retinal disease including retinitis pigmentosa. * Subject with serious history of hypersensitivity or allergy to investigational product. * Subject who Lost sight of one eye by Non-arteritic anterior ischemic optic neuropathy (NAION). * Subject with genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption. * Orthostatic hypotension * Subjects who is not able to comply with guidelines described in the protocol. * Subjects who is determined by investigator's decision as unsuitable for clinical trial participation.